鉅细胞动脉炎治疗市场规模、份额和成长分析：按治疗方法、给药途径、疾病严重程度、最终用户和地区划分 - 2026-2033 年行业预测

2024年全球鉅细胞动脉炎治疗市值为2.352亿美元，预计将从2025年的2.4578亿美元成长到2033年的3.4953亿美元。预测期（2026-2033年）的复合年增长率预计为4.5%。

由于人口老化和治疗方案的进步，全球鉅细胞动脉炎 (GCA) 治疗市场正经历显着增长，这表明治疗方案正从传统的高剂量糖皮质激素转向创新、可减少类固醇用量的生物製药，例如白细胞介素-6 抑製剂。这种转变满足了对有效治疗方法的迫切需求，这些治疗能够最大限度地减少全身併发症并预防不可逆的视力丧失。随着临床医生采用这些标靶治疗，真实世界临床数据证实，类固醇相关不利事件的发生率下降，减轻了医院的负担，并提高了生物製药的报销率。此外，血管成像技术和早期诊断的进步正在优化患者群体，而生物相似药和口服製剂的推出则促进了价格竞争。这些因素共同作用，提高了成熟市场和新兴市场的治疗可及性，从根本上重塑了治疗模式。

全球鉅细胞动脉炎治疗市场驱动因素

全球鉅细胞动脉炎治疗市场正受到生物製药已被证实能够改善症状控制并有效控制疾病。这一趋势促使专科医生更多地采用生物製剂，并延长患者的治疗疗程。因此，对已通过核准治疗方法的需求不断增长，促使供应商加大生产和分销投入，同时也刺激了下一代分子药物的竞争性研发。临床医生和患者对长期治疗信心的增强正在深化市场，促使支付方和医疗保健系统考虑扩大保险覆盖范围，并透过既定的治疗路径推动市场整体扩张。

全球鉅细胞动脉炎治疗市场的限制因素

全球鉅细胞动脉炎治疗市场面临严峻挑战，这主要是由于许多创新治疗方法的初始治疗和持续治疗费用高昂。这些经济负担加重了患者的经济压力，并加剧了医疗预算紧张，导致支付方实施限制性医疗保险政策并要求进行繁琐的预先核准流程。这些报销难题使得临床医生在开立昂贵治疗方法时犹豫不决，转而选择更传统的治疗方法。这种情况阻碍了资源匮乏地区市场的渗透，并限制了患者获得持续治疗的机会。因此，需求有限以及不同医疗体系间治疗资源分配不均严重阻碍了整体市场成长和先进治疗方法的普及应用。

全球鉅细胞动脉炎治疗市场趋势

全球鉅细胞动脉炎治疗市场正经历着一场变革，生物製药和生物相似药的激增推动了这一趋势，为医疗服务提供者和患者拓展了治疗选择。随着企业采取创新的商业策略，促进与支付方的合作并加强患者支持倡议，这一趋势正在提高药物的可及性，并促使这些治疗方法被纳入处方药目录。製造商日益注重高效生产和稳定供应，以满足不断增长的需求。对真实世界证据的日益重视，以及对医生教育的加强，正在导致治疗方案的差异化和竞争格局的加剧。这推动了创新的给药模式、用药依从性计划以及在多学科医疗机构中进行的综合疾病管理的发展。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

市场考察

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场吸引力指数
• PESTEL 分析
• 监理情势

全球鉅细胞动脉炎治疗市场规模：依治疗方法及复合年增长率划分（2026-2033 年）

• 皮质类固醇
  • 口服类固醇
  • 注射用皮质类固醇
• 生物製药
  • IL-6抑制剂
  • 抗TNF製剂

全球鉅细胞动脉炎治疗市场规模：依给药途径及复合年增长率划分（2026-2033 年）

• 口服
• 肠外给药

全球鉅细胞动脉炎治疗市场规模：依疾病严重程度及复合年增长率划分（2026-2033 年）

• 轻症病例
• 重症病例

全球鉅细胞动脉炎治疗市场规模：按最终用户和复合年增长率划分（2026-2033 年）

• 医院
• 专科诊所

全球鉅细胞动脉炎治疗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 2023-2025年营收年比比较

主要企业简介

• Genentech
• AstraZeneca
• Novartis
• Pfizer
• Roche
• Bristol-Myers Squibb
• AbbVie
• GSK
• Merck & Co.
• Boehringer Ingelheim
• Sanofi
• Takeda Pharmaceuticals
• Eli Lilly and Company
• Amgen
• Bayer
• Regeneron Pharmaceuticals
• UCB
• Gilead Sciences
• Horizon Therapeutics
• Mallinckrodt Pharmaceuticals

结论与建议

Global Giant Cell Arteritis Treatment Market size was valued at USD 235.2 Million in 2024 and is poised to grow from USD 245.78 Million in 2025 to USD 349.53 Million by 2033, growing at a CAGR of 4.5% during the forecast period (2026-2033).

The Global Giant Cell Arteritis (GCA) Treatment Market is experiencing significant growth due to an aging demographic and advancements in therapeutic options, signaling a shift from traditional high-dose glucocorticoids to innovative, steroid-sparing biologics like interleukin-6 inhibitors. This transition addresses the urgent need for effective therapies capable of minimizing systemic complications and preventing irreversible vision loss. As clinicians adopt these targeted treatments, real-world evidence shows decreased rates of steroid-related adverse effects, reducing hospital burdens and encouraging payer reimbursement for biologics. Furthermore, improvements in vascular imaging and early diagnosis are optimizing patient volumes, while the introduction of biosimilars and oral agents is creating competitive pricing dynamics. Collectively, these factors enhance treatment accessibility in both established and emerging markets, fundamentally reshaping the therapeutic landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Giant Cell Arteritis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Giant Cell Arteritis Treatment Market Segments Analysis

Global giant cell arteritis treatment market is segmented by treatment type, administration route, disease severity, end users and region. Based on treatment type, the market is segmented into Corticosteroids and Biologics. Based on administration route, the market is segmented into Oral Administration and Parenteral Administration. Based on disease severity, the market is segmented into Mild Cases and Severe Cases. Based on end users, the market is segmented into Hospitals and Specialty Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Giant Cell Arteritis Treatment Market

The Global Giant Cell Arteritis Treatment market is significantly driven by the growing clinical inclination towards biologic agents, recognized for their ability to improve symptom control and manage the disease effectively. This trend leads to increased adoption among specialists and extends treatment durations for patients. Consequently, there is a rising demand for approved therapies, prompting suppliers to invest in production and distribution while encouraging the competitive development of next-generation molecules. Enhanced confidence among clinicians and patients in long-term therapy deepens the market, pushing payers and healthcare systems to explore wider coverage options, thereby facilitating overall market expansion through established treatment pathways.

Restraints in the Global Giant Cell Arteritis Treatment Market

The Global Giant Cell Arteritis Treatment market faces significant challenges due to high acquisition and ongoing management costs associated with many innovative therapies. These financial burdens create affordability issues for patients and strain healthcare budgets, prompting payers to implement restrictive coverage policies and necessitate extensive prior authorization processes. Such reimbursement difficulties deter clinicians from prescribing expensive treatments, favoring more traditional therapies instead. This scenario hinders market penetration in resource-limited environments and restricts patients' access to continuous treatment. Consequently, the limited demand and inconsistent access throughout various healthcare systems substantially impede overall market growth and the adoption of advanced therapies.

Market Trends of the Global Giant Cell Arteritis Treatment Market

The Global Giant Cell Arteritis Treatment market is witnessing a transformative shift driven by the proliferation of biologics and biosimilars, enhancing therapeutic options for both healthcare providers and patients. This trend promotes accessibility and encourages the inclusion of these treatments in formularies, as companies adopt innovative commercial strategies that foster collaborations with payers and bolster patient support initiatives. Manufacturers are advancing their focus on efficient production and consistent supply to meet growing demand. The emphasis on real-world evidence, alongside enhanced physician education, distinguishes treatment options and sparks competitive dynamics that promote innovative delivery models, adherence programs, and comprehensive disease management in multidisciplinary care settings.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Giant Cell Arteritis Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Corticosteroids
  • Oral Corticosteroids
  • Injectable Corticosteroids
• Biologics
  • IL-6 Inhibitors
  • Anti-TNF Agents

Global Giant Cell Arteritis Treatment Market Size by Administration Route & CAGR (2026-2033)

• Market Overview
• Oral Administration
• Parenteral Administration

Global Giant Cell Arteritis Treatment Market Size by Disease Severity & CAGR (2026-2033)

• Market Overview
• Mild Cases
• Severe Cases

Global Giant Cell Arteritis Treatment Market Size by End Users & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics

Global Giant Cell Arteritis Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Administration Route, Disease Severity, End Users)
  • US
  • Canada
• Europe (Treatment Type, Administration Route, Disease Severity, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Administration Route, Disease Severity, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Administration Route, Disease Severity, End Users)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Administration Route, Disease Severity, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Genentech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mallinckrodt Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations